{"id":62115,"date":"2026-04-01T21:20:39","date_gmt":"2026-04-01T13:20:39","guid":{"rendered":"https:\/\/flcube.com\/?p=62115"},"modified":"2026-04-01T21:20:40","modified_gmt":"2026-04-01T13:20:40","slug":"merck-co-partners-with-infinimmune-for-838-million-antibody-discovery-collaboration-using-human-first-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62115","title":{"rendered":"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform"},"content":{"rendered":"\n<p><strong>Merck &amp; Co., Inc.<\/strong> (MSD; <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) announced a strategic collaboration with fellow US biotech <strong>Infinimmune<\/strong> to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune&#8217;s proprietary &#8220;<strong>human-first<\/strong>&#8221; antibody discovery platform in a deal worth up to <strong>USD 838 million<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed amount<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Multiple candidates eligible for development-based milestones<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>Up to USD 838 million<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Merck holds exclusive development and commercialization rights<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>Multiple undisclosed therapeutic targets specified by Merck<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-infinimmune-s-anthrobody-system\">Technology Platform \u2013 Infinimmune&#8217;s Anthrobody System<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-core-components\">Core Components<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anthrobody Discovery Platform<\/strong>: Enables direct screening from human immune repertoire<\/li>\n\n\n\n<li><strong>GLIMPSE Antibody Language Model<\/strong>: AI-powered optimization of therapeutic antibodies<\/li>\n\n\n\n<li><strong>Memory B Cell Screening<\/strong>: Capable of analyzing millions of individual memory B cells<\/li>\n\n\n\n<li><strong>Multiplex Target Capability<\/strong>: Simultaneous screening against hundreds of potential targets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-advantages\">Key Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Natural Pairing<\/strong>: Identifies naturally paired heavy and light chain antibody candidates<\/li>\n\n\n\n<li><strong>Rapid Selection<\/strong>: Accelerated identification of candidates with strong affinity and specificity<\/li>\n\n\n\n<li><strong>Drug-like Properties<\/strong>: Built-in selection for favorable developability characteristics<\/li>\n\n\n\n<li><strong>Human-Derived<\/strong>: Minimizes immunogenicity risk through native human antibody sequences<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-merck-amp-co\">For Merck &amp; Co.<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Expansion<\/strong>: Access to cutting-edge antibody discovery technology without internal platform development<\/li>\n\n\n\n<li><strong>Speed to Clinic<\/strong>: Accelerated timeline from target identification to clinical candidate selection<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Leverages natural human immune responses rather than engineered libraries<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Strengthens position in highly competitive antibody therapeutics market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-infinimmune\">For Infinimmune<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Validation<\/strong>: Major pharma partnership validates platform capabilities and commercial potential<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Significant milestone-based revenue stream across multiple programs<\/li>\n\n\n\n<li><strong>Platform Demonstration<\/strong>: Opportunity to showcase technology against diverse therapeutic targets<\/li>\n\n\n\n<li><strong>Industry Credibility<\/strong>: Association with Merck enhances reputation among potential future partners<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antibody Therapeutics Market<\/strong>: Global market projected to exceed $300 billion by 2030<\/li>\n\n\n\n<li><strong>Discovery Platform Competition<\/strong>: Competes with traditional hybridoma, phage display, and transgenic mouse platforms<\/li>\n\n\n\n<li><strong>AI Integration Trend<\/strong>: Part of broader industry shift toward AI\/ML-enhanced drug discovery<\/li>\n\n\n\n<li><strong>Human-First Approach<\/strong>: Addresses limitations of engineered libraries that may not reflect natural immune responses<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-operational-implications\">Financial &amp; Operational Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Merck Investment<\/strong>: Modest upfront commitment with significant milestone-based payments tied to success<\/li>\n\n\n\n<li><strong>Infinimmune Resources<\/strong>: Expected to expand platform capacity and team to support Merck collaboration<\/li>\n\n\n\n<li><strong>Timeline Expectations<\/strong>: First candidates expected within 12-18 months based on platform speed claims<\/li>\n\n\n\n<li><strong>Geographic Focus<\/strong>: US-based collaboration maintains domestic innovation ecosystem<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the collaboration agreement, platform capabilities, and financial terms. Actual results may differ due to risks including technical feasibility, development challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4669,2675,176,903],"class_list":["post-62115","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-infinimmune","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech Infinimmune to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune&#039;s proprietary &quot;human-first&quot; antibody discovery platform in a deal worth up to USD 838 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62115\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech Infinimmune to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune&#039;s proprietary &quot;human-first&quot; antibody discovery platform in a deal worth up to USD 838 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62115\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T13:20:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T13:20:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62115#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62115\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform\",\"datePublished\":\"2026-04-01T13:20:39+00:00\",\"dateModified\":\"2026-04-01T13:20:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62115\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Infinimmune\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62115#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62115\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62115\",\"name\":\"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-01T13:20:39+00:00\",\"dateModified\":\"2026-04-01T13:20:40+00:00\",\"description\":\"Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech Infinimmune to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune's proprietary \\\"human-first\\\" antibody discovery platform in a deal worth up to USD 838 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62115#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62115\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62115#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech Infinimmune to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune's proprietary \"human-first\" antibody discovery platform in a deal worth up to USD 838 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62115","og_locale":"en_US","og_type":"article","og_title":"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform","og_description":"Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech Infinimmune to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune's proprietary \"human-first\" antibody discovery platform in a deal worth up to USD 838 million.","og_url":"https:\/\/flcube.com\/?p=62115","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T13:20:39+00:00","article_modified_time":"2026-04-01T13:20:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62115#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62115"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform","datePublished":"2026-04-01T13:20:39+00:00","dateModified":"2026-04-01T13:20:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62115"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Infinimmune","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62115#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62115","url":"https:\/\/flcube.com\/?p=62115","name":"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-01T13:20:39+00:00","dateModified":"2026-04-01T13:20:40+00:00","description":"Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech Infinimmune to identify and develop antibody drug candidates against multiple undisclosed targets, leveraging Infinimmune's proprietary \"human-first\" antibody discovery platform in a deal worth up to USD 838 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62115#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62115"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62115#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck &amp; Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62115"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62115\/revisions"}],"predecessor-version":[{"id":62116,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62115\/revisions\/62116"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}